Intraepithelial neutrophils in pediatric severe asthma are associated with better lung function  by Andersson, Cecilia K. et al.
Intraepithelial neutrophils in pediatric severe
asthma are associated with better lung functionCecilia K. Andersson, PhD,a Alexandra Adams, MBBS,a,b* Prasad Nagakumar, MBBS,a,b* Cara Bossley, MDRes,b
Atul Gupta, MDRes,b Daphne De Vries, BSc,a Afiqah Adnan, BSc,a Andrew Bush, MD,b Sejal Saglani, MD,a,b and
Clare M. Lloyd, PhDa London, United KingdomBackground: Neutrophils and IL-17A have been linked
mechanistically in models of allergic airways disease and have
been associated with asthma severity. However, their role in
pediatric asthma is unknown.
Objectives: We sought to investigate the role of neutrophils and
the IL-17A pathway in mediating pediatric severe therapy-
resistant asthma (STRA).
Methods: Children with STRA (n 5 51; age, 12.6 years; range,
6-16.3 years) and controls without asthma (n 5 15; age,
4.75 years; range, 1.6-16 years) underwent clinically indicated
fiberoptic bronchoscopy, bronchoalveolar lavage (BAL),
endobronchial brushings, and biopsy. Neutrophils, IL-17A, and
IL-17RA–expressing cells and levels of IL-17A and IL-22 were
quantified in BAL and biopsies and related to clinical features.
Primary bronchial epithelial cells were stimulated with IL-17A
and/or IL-22, with and without budesonide.
Results: Children with STRA had increased intraepithelial
neutrophils, which positively correlated with FEV1 %predicted
(r 5 0.43; P 5 .008). Neutrophilhigh patients also had better
symptom control, despite lower dose maintenance inhaled
steroids. Submucosal neutrophils were not increased in children
with STRA. Submucosal and epithelial IL-17A–positive cells
and BAL IL-17A and IL-22 levels were similar in children with
STRA and controls. However, there were significantly more IL-
17RA–positive cells in the submucosa and epithelium in
children with STRA compared with controls (P 5 .001).
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Conclusions: A proportion of children with STRA exhibit
increased intraepithelial airway neutrophilia that correlated
with better lung function. STRA was also characterized by
increased airway IL-17RA expression. These data suggest a
potential beneficial rather than adverse role for neutrophils in
pediatric severe asthma pathophysiology. (J Allergy Clin
Immunol 2016;nnn:nnn-nnn.)
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Severe asthma is heterogeneous and can be divided into
subphenotypes.1-3 Severe therapy-resistant asthma (STRA) af-
fects a small proportion of children with asthma and is character-
ized by persistent symptoms, acute severe exacerbations, and/or
fixed airflow obstruction despite treatment with high-dose steroid
therapy, and after modifiable factors such as poor adherence and
persistent allergen exposure have been addressed.4 Because TH2-
mediated eosinophilic asthma generally responds well to steroid
treatment, the lack of responsiveness to steroids in STRA sug-
gests an alternative inflammatory pathway in these children. We
have previously shown that children with STRA exhibit airway
eosinophilia and remodeling, but a paucity of classical TH2 cyto-
kines (IL-4, IL-5, and IL-13).5
In adults, airway neutrophils have been associated with
increased asthma severity1,6,7 but their functional role in medi-
ating disease pathophysiology is unclear. Elevated levels of IL-
17A have been reported in sputum, bronchoalveolar lavage
(BAL) fluid, and peripheral blood8-11 in those with severe asthma
and have been implicated in pathogenesis.10,12 In contrast, little is
known about the role of neutrophils and the IL-17 pathway in
children with STRA. IL-17A can induce bronchial epithelial
secretion of proinflammatory cytokines including the neutrophil
chemoattractants GRO and IL-8. It is proposed that IL-17A can
therefore induce neutrophilic airway inflammation and promote
steroid resistance in adults with severe asthma.13 Moreover, IL-
17A may also be involved in airway remodeling. IL-17A has
been reported to increase airway smooth muscle contraction on
methacholine stimulation and drive migration of airway smooth
muscle cells in murine models of allergic inflammation and in pa-
tients with asthma.9,14,15 IL-17A binds to the receptor subunits IL-
17RA and C, which are expressed on epithelial and mesenchymal
cells as well as on some immune cell populations such as lympho-
cytes, dendritic cells, and monocytes/macrophages in the lung.16
Mice that lack IL-17RA produce less CXCL1 and CXCL2 on pul-
monary challenge with Klebsiella pneumoniae17 and IL-17RA
signaling is also necessary for host defense against Candida albi-
cans.18 In 2 mouse models, blocking IL-17R and IL-17RB1
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TH17 cells also secrete IL-22, and IL-22 mRNA is elevated in
PBMCs in pediatric patients with severe asthma, and rhinitis.19
Although IL-22 has been described as a proinflammatory cyto-
kine causing airway hyperreactivity in mice and remodeling in
both epithelial and airway smooth muscle cells in humans, it
has also been shown to reduce inflammation by suppressing cyto-
kine production from epithelial cells. Taken together, data suggest
that IL-22 plays different roles in various phases of airway
inflammation.20,21
We have previously reported that there was no increase in
mucosal or BAL neutrophils in patients with STRA. However,
when reexamining biopsy slides, we noted that some but not all of
these children had intraepithelial neutrophils. We therefore
hypothesized that intraepithelial neutrophils, together with
elevated IL-17A and IL-22, would be associated with worse
asthma severity. We determined the extent of neutrophilic
inflammation in a new cohort of children with STRA and
investigated IL-17A and IL-22 levels and their cellular sources
in BAL. We assessed the response of bronchial epithelial cells to
IL-17A, IL-22, and steroids in patients with STRA compared with
controls. The findings were then related to key clinical features
and airway remodeling and were confirmed in archived biopsies
from an older cohort of children with STRA to look specifically at
intraepithelial neutrophils, which have not previously been
reported.METHODS
Subjects
Fifty-one school-aged children with STRA22 (age, 12.6 years; range,
6-16.3 years) were recruited from the Royal Brompton Hospital. They
underwent detailed clinical assessments including spirometry, exhaled
nitric oxide measurements, and symptom scores followed by a clinically
indicated bronchoscopy, endobronchial brushings, BAL, and endobron-
chial biopsies to characterize airway pathology and develop customized
treatment plans.4 All children had previously undergone a detailed
assessment to ensure any modifiable factors such as poor adherence
or persistent allergen exposure had been addressed before the
bronchoscopy.23 Atopy was defined as at least 1 positive specific IgE
radioallergosorbent test result (>_0.35 kUI/L) to aeroallergens (house dust
mite, cat, dog, and grass pollen) and quantified as the sum of specific
IgE levels of these aeroallergens. Fifteen control subjects without
asthma (age, 4.75 years; range, 1.6-16 years) were either (A) having a
bronchoscopy to investigate upper airway symptoms and agreed to extra
research samples being taken or (B) undergoing general anesthesia for
cardiac catheterization and agreed to have a research bronchoscopy at
the same time (for details, see Table I and Table E2 in this article’s Online
Repository at www.jacionline.org). The study was approved by the
National Research Ethics Service Committee London - Chelsea, and
informed parental consent and child assent were obtained. In addition to
the above-mentioned cohort, findings relating to intraepithelial
inflammation were confirmed in biopsies obtained from a previously
published cohort5 of children with STRA (n 5 21) and controls (n 5 5).
In all figures, the latter will appear as gray symbols and their clinicaldetails are described in detail in this article’s Online Repository and in
Table E1 in the Online Repository at www.jacionline.org. Inclusion of
both cohorts of children is of vital importance to the strength of the find-
ings because we were able to replicate the finding even in this second
cohort. There is no duplication of the data because we merely used the
archived biopsy samples to examine neutrophils, which had not previously
been examined in these samples. Further details of investigations are given
in the Methods section in this article’s Online Repository at www.
jacionline.org.Epithelial culture and stimulation
Primary bronchial epithelial cells (PBECs) were seeded into tissue culture
flasks containing bronchial epithelial growthmedium and used at passage 3 for
all experiments. PBECs were stimulated with recombinant human IL-17A
(eBioscience, San Diego, Calif) and IL-22 (eBioscience) alone, or to cells
pretreated with budesonide (Breath Limited, Barnstaple, United Kingdom) as
stated in Zijlstra et al.24 Culture supernatants were collected after 24 hours and
samples for mRNA extraction were harvested after 8-hour stimulation (see
this article’s Online Repository).Quantification of cytokines
Cell culture supernatant was collected and cytokines analyzed using
ELISA and Milliplex human cytokine panel I and II (see this article’s Online
Repository).Cytomix
BAL cytokine quantification was performed using Flowcytomix Human
TH1/TH2/TH9/TH17/TH22 13 plex multiplex (eBioscience) (see this article’s
Online Repository).Flow cytometry
Lymphocytes used for compensations and fluorescence minus ones were
extracted fromperipheral blood and cells from the airway lumenwere obtained
after centrifuge of BAL fluid. Cells were stained for extracellular markers
CD3, CD4, CD8, CD161, and gdTCR and intracellular IL-17A (eBiosciences,
mouse anti-human 5 mL per well) (see this article’s Online Repository).RNA extraction and real-time PCR
Total RNA was extracted from epithelial cells using the Qiagen RNeasy
Mini Kit (Qiagen, Hilden, Germany). cDNAwas synthesized from 500 ng of
total RNA and analyzed by using High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, Calif) (see this article’s Online
Repository).Histopathology
Endobronchial biopsies were processed to paraffin. Five-micrometer
sections were stained with hematoxylin and eosin and used to assess
morphology and consecutive sections were used for Masson’s trichrome
(Sigma Aldrich, Gillingham, United Kingdom) for collagen staining, Congo
red for staining of eosinophils, and immunohistochemical staining for IL-17A,
IL-17RA, and neutrophil elastase (see this article’s Online Repository).Statistical analysis
Sample size was opportunistic because there are no data to inform a power
calculation. Nonparametric tests including Mann-WhitneyU test and Kruskal
Wallis test with Bonferroni post hoc test were used to detect differences be-
tween 2 groups or more than 2 groups, respectively, using GraphPad Prism
6 (GraphPad Software, La Jolla, Calif). Correlations were assessed using
the Spearman rank correlation test. P value of less than .05 was considered
significant.
TABLE I. Demographic characteristics of children with STRA and control patients undergoing bronchoscopy
Characteristic STRA (n 5 51)
Controls without
asthma* (n 5 15) P value
Atopy 45 of 51 (88.2%) 1 of 15 (6.6%) .005
Male:female 30:21 8:7
Age (y) 12.6 (6 to 16.3) 4.75 (1.6 to 16) .005
Duration of symptoms (y) 7 (3.5 to 14.3)
Weight (kg) 41.7 (22.3 to 99.9) 19.2 (8.9 to 68)
Weight z score 0.5 (23.4 to 3.7) 0.4 (23.1 to 3.4)
Height (cm) 150 (106 to 188)
Height z score 0.02 (23.9 to 2.88)
Intubation for asthma 4 of 51 (7.8%)
Total IgE (IU/mL) 419 (20 to 4867) 46.5 (1 to 210) .003
Sum of inhalant specific IgE (IU/mL) 7.4 (0 to 321) 0.54 (0 to 20) .1
Sum of all specific IgE (IU/mL) 11.3 (0 to 321) 1.1 (0 to 20) .2
BAL neutrophils (%) 3.7 (1 to 21.7) 5.4 (4 to 9) .35
BAL eosinophils (%) 3 (0.3 to 23) 2 (0 to 5) .17
Blood eosinophils (%) 7.5 (0 to 21.4) 3.5 (0.9 to 9.8) .06
Blood neutrophils (%) 51 (6 to 87) 49 (31 to 71) .4
ACT score 13 (5 to 23)
ACT normal (>19/25) 10 of 51 (19.6%)
Baseline FEV1 (L) 1.75 (0.45 to 3.95)
Baseline % predicted FEV1§ 89.4 (24 to 126)
Number FEV1 ‘‘normal’’ (>80% predicted) 31 of 51 (60.7%)
Baseline FVC (L) 2.36 (1.37 to 5.39)
Baseline % predicted FVC 99.5 (63 to 133)
Baseline bronchodilator reversibility (%) 11.4 (23 to 66.7)
Baseline FENO50 (ppb)k 46.2 (5.4 to 164.8)
Medications
Daily dose inhaled{ corticosteroid (mg/d) budesonide equivalent 1400 (500 to 2000) 0 (0 to 200)
Leukotriene receptor antagonist 46 of 51 (90.1%) 0
Systemic corticosteroids 6 of 51 (11.7%) 0
Daily dose (mg/d) 6.25 (2.5 to 20)
Theophylline 4 of 51 (7.8%) 0
Data presented as median (range).
*Eighty percent of the controls without asthma had symptoms such as stridor (tracheal stenosis, laryngotracheomalacia), reflux, dry cough, or hemoptysis. The remaining 20% were
undergoing general anesthesia for elective cardiac catheterization and had agreed to a research bronchoscopy. For details of diagnosis in controls without asthma, see Table E2.
Differences between groups were assessed by Mann-Whitney test where P < .05 is significant.
BAL neutrophils (<3% is normal).
BAL eosinophils (<3% is normal).
§FEV1: presented as percentage predicted.
jjFENO: fractional exhaled nitric oxide measured at 50 L/min.
{ICS: inhaled corticosteroids/d.
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Patients’ demographic characteristics
Clinical characteristics are presented in Table I. BAL bacterial
culture was positive in 9 of 51 (15.6%) and BAL viral PCR was
positive in 5 of 51 (9.8%) patients with STRA. There was a
parental report of exposure to tobacco smoke in 15 of 41 (37%)
patients with STRA, which was confirmed using urinary cotinine
levels.A subgroup of STRA is characterized by increased
intraepithelial neutrophils
Previous findings from our group5 that showed increased BAL
and submucosal eosinophils in children with STRA compared
with controls were confirmed in the present study (Fig 1, A and
B and D and E). However, when investigating intraepithelial
eosinophils in both the present and the previous cohort,5 we
found no eosinophils in the epithelium of controls or children
with STRA (Fig 1, C and F). Because severe asthma in adult
patients13 and in murine models10,25-27 has been associated withneutrophilia, we quantified the number of neutrophils in the sub-
mucosa and epithelium in endobronchial biopsies from children
with STRA and controls. In keeping with our previous findings,5
neutrophil counts were not increased in the submucosa of children
with STRA compared with controls (P5 .9; Fig 1, G and H and J
and K). However, intraepithelial neutrophils, expressed both as
proportion of all neutrophils in the biopsy and as neutrophils
per length basement membrane, were significantly higher in chil-
dren with STRA than in controls (P5 .01 and .007, respectively)
(Fig 1, I and L). We also confirmed the increase in intraepithelial
neutrophils in STRA in biopsies obtained from a previous cohort5
of children with STRA (Fig 1, I, shown as gray symbols; for clin-
ical details of these patients, see Table E1). The patients with in-
traepithelial neutrophils (referred to as Neutrophilhigh) had a
median of 0.02 neutrophils per length of reticular basement mem-
brane (range, 0.004-0.04) compared with Neutrophillow patients
(0; range, 0-0) (P5 .007). There was no difference in the number
of intraepithelial neutrophils between patients with STRA treated
with maintenance oral and inhaled steroids compared with those
treated with only inhaled steroids (P 5 .8).
FIG 1. Eosinophils and neutrophils in different lung compartments.
Eosinophil percentage in BAL (A) (controls n 5 11, STRA n 5 31), numbers
per area of submucosa (B) (controls without asthma n 5 7, STRA n 5 20),
and intraepithelial eosinophils per length of reticular basement membrane
(C) (controls n 5 7, STRA n 5 20). Representative micrographs of Congo
Red stain for eosinophils in controls without asthma (D) and patients with
STRA (E). F, High magnification picture of epithelium with no eosinophils
in patients with STRA. Neutrophil percentage in BAL (G) (controls without
asthma n5 12, STRA n5 52), numbers per area of submucosa (H) (controls
without asthma n5 10, STRA n5 28), and proportion of intraepithelial neu-
trophils (I) (controls without asthma n 5 13, STRA n 5 37). Representative
micrographs of immunohistochemical stain for elastase in controls without
asthma (J) and patients with STRA (K). L, High magnification picture of in-
traepithelial neutrophils in patients with STRA. Scale bar: 200 mm (Fig 1, D
and J), 100 mm (Fig 1, E and K), 20 mm (Fig 1, F), and 10 mm (Fig 1, L). Sta-
tistical significance between controls without asthma and patients with
STRA was tested using Mann-Whitney test. *P < .05, **P < .01, and ***P
< .001.
J ALLERGY CLIN IMMUNOL
nnn 2016
4 ANDERSSON ET ALChildren with STRA did not have increased BAL or
tissue IL-17A
To investigate any relationship between neutrophils and airway
IL-17A in children with STRA, endobronchial biopsies were
stained for IL-17A. IL-17A expression was observed in small
mononuclear cells as well as in a larger mononuclear cellpopulation in the adventitia of the bronchial wall, but there was
no difference in the number of IL-17A–positive cells between
controls and patients with STRA (Fig 2, A and B). No IL-17A
expression was seen within the epithelium (Fig 2, A and C).
Although undetectable in most samples, IL-17A levels in BAL
were similar in children with STRA and controls (Fig 2, D). IL-
22 was detected in BAL fluid in 15 of 25 controls (60%) and 25
of 37 patients with STRA (68%). However, IL-22 levels were
similar in both groups (Fig 2, E). There was also no difference
in the proportion of TH17 (CD4
1IL-171) (Fig 2, F) or IL-171
gdT cells (Fig 2, G) in BAL from children with STRA compared
with controls.Children with STRA had increased submucosal and
epithelial expression of IL-17RA
We further wanted to investigate the tissue expression of the
receptor for IL-17A. IL-17RA was expressed in small mono-
nuclear and polymorphonuclear cells in the submucosa in
controls (Fig 3, A) and patients with STRA (Fig 3, B). Strong
expression was also present in the epithelium of patients with
STRA (Fig 3, B). There was significantly increased expression
of IL-17RA in both submucosa (Fig 3, C) and epithelium (Fig
3, D) expressed as positive pixels per area (positivity) in patients
with STRA compared with controls. Epithelial IL-17R expression
remained elevated in patients with STRA even after excluding the
patients with a positive bacterial culture or viral detection
(P 5 .006). There was no difference in IL-17RA expression be-
tween the patients taking maintenance oral steroids and inhaled
steroids compared with those only on inhaled steroids (P 5 .3).
Because intraepithelial IL-17R expression was significantly
increased in patients with STRA, we determined how the
bronchial epithelium responds to stimulation with IL-17A alone
or in combination with budesonide. mRNA expression of IL-
17RA and C was comparable between patients with STRA and
controls at baseline, but expression was significantly increased in
patients with STRA compared with controls following IL-17A
stimulation alone, and with the addition of budesonide to cultures
(Fig 3, E and F). Furthermore, better symptom control, measured
using the asthma control test (ACT), correlated with increased IL-
17RA expression in the epithelial compartment in children with
STRA (Fig 3, G).IL-17A stimulation of bronchial epithelial cells from
children with STRA induced IL-8 secretion
Because IL-8 is a neutrophil chemoattractant and we had seen
increased intraepithelial neutrophils in patients with STRA, levels
of IL-8 were measured in BAL fluid. IL-6 was measured as a
comparativemarker of a general inflammatory response. BAL IL-
8 and IL-6 levels were similar in patients with STRA and controls
(Fig 4, A andB). This was unchanged after patients with a positive
BAL bacterial culture or viral detection were excluded. IL-17A
has previously been shown to induce IL-8 from bronchial epithe-
lial cells.28 To investigate the relationship between IL-17A,
epithelial cells, and neutrophils, we measured IL-8 secretion
from PBEC culture supernatants following IL-17A and IL-22
stimulation, with or without budesonide. PBECs from patients
with STRA secreted significantly higher amounts of IL-8
compared with cells from control patients. This effect was
observed following stimulation with IL-17A alone, in
FIG 2. Sources and expression of IL-17A in children with STRA compared with controls without asthma.
Representative micrograph of immunohistochemical stain for IL-17A in children with STRA (A). Scale bar:
100 mm. Quantification of the number of IL-17A–expressing cells per area in submucosa (B) (controls
without asthma n 5 6, STRA n 5 39) and bronchial epithelium (C) (controls without asthma n 5 6, STRA
n 5 32). BAL levels of IL-17A (D) (controls without asthma n 5 11, STRA n 5 23) and IL-22 (E) (controls
without asthma n 5 11, STRA n 5 23) in controls without asthma and children with STRA. Percentages
of IL-17A–expressing TH17 (F) (controls without asthma n5 10, STRA n5 13) and gamma delta (G) (controls
without asthma n 5 8, STRA n 5 11) lymphocytes in children with STRA compared with controls without
asthma. Statistical significance between controls without asthma and children with STRA was tested using
Mann-Whitney test. NS, Not significant.
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tantly, IL-8 secretion was unaffected by the presence of budeso-
nide (Fig 4, C). In contrast, levels of epithelial IL-6 secretion
were comparable between patients with STRA and controls
(Fig 4, D). Levels of IL-13 (TH2 cytokine) and IFN-g (TH1 cyto-
kine) in epithelial cell culture supernatants were similar between
patients with STRA and controls. However, levels of the neutro-
phil chemoattractant GRO were increased in patients with STRA
compared with controls on IL-17A stimulation (see Fig E1 in this
article’s Online Repository at www.jacionline.org).
To further investigate the link between increased IL-17A
receptor expression, intraepithelial neutrophils, and a clinical
phenotype, correlations with clinical parameters were performed.
We found no correlations with any confounding factor such as age
or body mass index in children with STRA. Neither was there any
association between intraepithelial neutrophils and parental
smoking status or BAL bacteriology/virology (Table II). Tissue
expression of IL-17A and IL-17RAwas also compared in patients
with and without intraepithelial neutrophils. Although nosignificant differences were found, there was a trend for increased
epithelial IL-17RA expression in the group with intraepithelial
neutrophils (see Fig E3 in this article’s Online Repository at
www.jacionline.org). Two subpopulations of children with
STRA were apparent on the basis of the presence or absence of
intraepithelial neutrophils. Patients were therefore divided into
intraepithelial Neutrophilhigh and Neutrophillow groups. There
were no differences in the number of submucosal, epithelial, or
BAL eosinophils (Fig 4, E and F), total IgE (Fig 4,G), or fraction
of exhaled nitric oxide (Fig 4, H) between the Neutrophilhigh and
Neutrophillow groups. There was no relationship between retic-
ular basement membrane thickness, a marker of airway remodel-
ing, and intraepithelial neutrophils (see Fig E5, E, in this article’s
Online Repository at www.jacionline.org). However, the Neutro-
philhigh patients with STRA had a significantly higher ACT score
(Fig 4, I) and were prescribed lower dose maintenance inhaled
corticosteroids compared with the Neutrophillow patients with
STRA. FEV1 %predicted (Fig 4, K) was significantly higher in
the Neutrophilhigh patients with STRA, and the proportion of
FIG 3. Representative micrographs of immunohistochemical stain for IL-17RA in controls without asthma
and patients with STRA (A and B, respectively). Scare bar 100 mm (Fig 3, A) and 50 mm (Fig 3, B). Quantifi-
cation of the expression (positive pixels per area) of IL-17RA in submucosa (controls without asthma n5 6,
STRA n 5 31) and epithelium (controls without asthma n 5 6, STRA n 5 24) (C and D, respectively). mRNA
expression of IL-17RA and C in PBECs after stimulation with IL-17A and budesonide (Bud) (controls without
asthma n5 3, STRA n5 3) (E and F, respectively). Correlations between ACT score and IL-17RA expression
in epithelium (G) (n5 21). Statistical significance between controls without asthma and children with STRA
was tested using Mann-Whitney test and correlation analysis was performed using Spearman rank test,
where a P value of less than .05 was considered significant. *P < .05, **P < .01, and ***P < .001.
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FIG 4. Levels of IL-8 (A) (controls without asthma n5 9, STRA n5 24) and IL-6 (B) (controls without asthma
n 5 12, STRA n 5 23) in BAL. Levels of IL-8 (C) and IL-6 (D) in culture supernatant from PBECs after stimu-
lation with IL-17A, IL-22, and budesonide (controls n 5 4, STRA n 5 7). Differences in submucosal eosino-
phils (E) (Neuhi n 5 10, Neulo n 5 15), BAL eosinophils (F) (Neuhi n 5 12, Neulo n 5 20), total IgE (G) (Neuhi
n5 10, Neulo n5 21), FENO (H) (Neuhi n5 11, Neulo n5 18), ACT score (I) (Neuhi n5 12, Neulo n5 20), dose of
inhaled corticosteroids (J) (Neuhi n 5 12, Neulo n 5 21), and FEV1 % predicted (K) within the group of chil-
dren with STRA based on the presence of intraepithelial neutrophils (Neuhi n 5 13, Neulo n 5 21). Correla-
tions between FEV1 % predicted and proportion of intraepithelial neutrophils (L) (n 5 36). Patients from the
cohort previously published in Bossley et al5 are shown in gray. Statistical significance between controls
and patients with STRA was tested using Mann-Whitney test and correlation analysis was performed using
Spearman rank test, where a P value of less than .05 was considered significant. FENO, Fraction of exhaled
nitric oxide. *P < .05.
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dicted (Fig 4, L).DISCUSSION
We have shown that a subgroup of children with STRA have
increased intraepithelial neutrophils compared with younger
controls without asthma, which, surprisingly and contrary to
our hypothesis, was associated with better FEV1 %predicted,
symptom score, and lower maintenance inhaled steroids. In
contrast, there were no intraepithelial eosinophils apparent in pa-
tients with STRA. Although there was no difference in tissue orluminal IL-17A, pediatric patients with STRA exhibited
increased submucosal and epithelial expression of IL-17R.
Collectively, our data indicate a potential beneficial role for intra-
epithelial neutrophils in this subphenotype of asthma.
The association between intraepithelial neutrophils and higher
FEV1, higher ACT score, and less inhaled corticosteroid treat-
ment suggests that neutrophils specifically within the epithelium
may have a protective role in this asthma phenotype. Most previ-
ous studies were in adult patients with asthma and very few
(including ourselves) have looked at the specific localization of
neutrophils within the airway.6,7,29 Having found a relationship
between intraepithelial neutrophils and lung function in the
TABLE II. Neutrophil, IL-17A, and IL-17RA quantification in relation to BAL bacteriology, virology, and parental smoking status
Parameter STRA (n 5 51) Controls without asthma (n 5 15) P value
BAL bacteriology (positive) 8 of 51 (15.4%) 1 of 15 (6.6%)
BAL virology (positive) 5 of 51 (9.8%) 1 of 15 (6.6%)
Parental smoking (positive) 15 of 41 (37%)
Cotinine levels (ng/mL)* 1.3 (1-4.8)
IL-17A (submucosa) 0.09 (0.03-0.3) 0.03 (0.02-0.07) .001
IL-17RA (submucosa) 20 (0-291) 9 (0-47) .4
IL-17RA (epithelium) 0.2 (0.01-0.5) 0.02 (0.007-0.08) .0006
Neutrophils (submucosa) 8 (0-202) 8 (0-36) .9
Neutrophils (epithelium), % 0 (0-60) 0 (0-0) .04
Eosinophils (submucosa) 54 (4-263) 8 (0-56) .01
Eosinophils (epithelium), % 0 (0-0) 0 (0-0) >.999
Comparison of intraepithelial neutrophils in STRA groups based on:
Positive Negative
BAL bacteriology 0 (0-17) 0 (0-60) .7
BAL virology 8 (0-17) 0 (0-60) .3
Parental smoking 0 (0-20) 0 (0-60) .9
Data presented as median (range).
*>4.8 ng/mL indicates exposure to tobacco smoke and >50 ng/mL is indicative of active tobacco smoking.
Cells per mm2.
Positivity (positive pixels per all pixels). Differences between groups were assessed by Mann-Whitney test where P < .05 is significant.
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8 ANDERSSON ET ALchildren reported here, we retrospectively quantified epithelial
neutrophils in archived biopsies from our previously published
cohort.5 The biopsies from the older cohort had not previously
been assessed for intraepithelial neutrophils and confirmed an as-
sociation between intraepithelial neutrophils and better spirom-
etry, a significant strength of the study. Unlike intraepithelial
neutrophils, eosinophils were not present within the epithelium
of children with STRA. However, the increased eosinophils in
the submucosa and lumen that we have reported previously5
were confirmed here (Fig 1, A and B). Although we cannot
confirm a direct functional role of neutrophils in pediatric
STRA, the localization of these cells within the epithelium may
point to a specific role in host defense in this phenotype. Data
from adults suggest that there may be at least 2 phenotypes asso-
ciated with airway neutrophilia: beneficial as a response to infec-
tions, or harmful potentially driven by environmental irritants
such as tobacco smoke.30 Exposure to viruses, bacterial endo-
toxins, and air pollution are common triggers of a neutrophil-
rich inflammation and consequently could lead to asthma
symptoms. Other studies have shown increased numbers of intra-
epithelial neutrophils in various bacterial, viral, and fungal infec-
tions as well as in cystic fibrosis and chronic obstructive
pulmonary disease.31-35 However, we found no association be-
tween intraepithelial neutrophils and BAL bacteriology/virology
or parental smoking status. Only 1% of bacteria can be cultured36;
therefore, we cannot rule out that the children had other infections
or an alteredmicrobiota thatwe could not detect.37 It is also impor-
tant to highlight that the children in this study were clinically sta-
ble and had at least 2 weeks since any exacerbation at the time of
bronchoscopy. Because neutrophils have a high turnover and short
lifespan, it is likely that the neutrophils observedwithin the epithe-
lium in these patients are inherently present as opposed to re-
cruited in response to an insult during an exacerbation.
There is an increasing need to find biomarkers that will indicate
subgroups of patients (TH2-low, Neutrophil
high) to enable effec-
tive personalized therapies. Other studies have identified thatBAL and sputum neutrophils are more abundant in patients
with severe asthma.7,38 In a study investigating the molecular
phenotype of severe asthma in children, both neutrophils and eo-
sinophils were found to be elevated in BAL fluid from children
with severe asthma compared with adult controls.39 These chil-
dren also had high levels of GRO and IL-8 in BAL fluid.39 How-
ever, the specific location of neutrophils in the subcompartments
of the bronchial wall was not investigated. The neutrophils in our
study are intraepithelial and hence unlikely to result in a predic-
tive biomarker in the periphery or airway lumen. However, mol-
ecules that represent intraepithelial neutrophils could be
investigated in induced sputum in future studies. Unfortunately,
wewere unable to collect sputum from enough patients with intra-
epithelial neutrophils to undertake such an analysis.
It is possible that the intraepithelial neutrophils might be
migrating through the epithelium into the lumen.33-35 But the
increased epithelial expression of IL-17R, as well as the increased
local epithelial production of neutrophil chemoattractants
including IL-8 and GRO that we have demonstrated, suggest
that neutrophils are trapped in the epithelial layer in children
with STRA. Although speculative and further investigation is
warranted, this might indicate an epithelial microenvironment
that is dependent on altered expression of epithelial adhesionmol-
ecules that results in trapping of neutrophils in the epithelial
layer.36,37
There is scant information regarding the role of IL-17A in
pediatric STRA. Higher numbers of IL-17A–positive cells have
been found in the bronchial submucosa from adults with severe
asthma compared with controls.8 IL-17 mRNA and numbers of
IL-17–positive lymphocytes are also increased in BAL from pa-
tients with asthma.10,11,40 A recent study that has investigated
the TH17 high phenotype in adult asthma has shown that a
TH17 high signature is associated with steroid-dependent moder-
ate-to-severe asthma and eosinophilia.41 But despite this signa-
ture there were no significant differences in lung function
between patients. In addition, when IL-17 was blocked in a
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ease, therewas no impact on lung function, eosinophils, or neutro-
phils.41 Other studies have shown that TH17-mediated airway
inflammation is steroid resistant.42 Furthermore, Nanzer et al43
reported that PBMCs from adults with severe asthma exhibited
increased levels of TH17 cytokines, which were not inhibited by
steroids.
We were careful to ensure all reagents were IL-17A specific,
eliminating effects of contamination with IL-17F. Although
significantly higher serum levels of IL-17A have been reported
in children with asthma exposed to diesel exhaust particles,44 we
found no increase in IL-17A in BAL fluid. Importantly, IL-17A
levels were detectable, but similar between patients with STRA
and controls, suggesting little influence from dilution effects of
BAL. However, this might be because samples were collected
during stable disease rather than following challenge or during
disease exacerbation. After performing a double stain with IL-
17A and themajor leukocyte populations, we found that themajor
cell types in the submucosa expressing IL-17Awere CD31 lym-
phocytes and neutrophils. However, neither the epithelial cells nor
infiltrating leukocytes within the epithelium were IL-17A posi-
tive. In contrast, our patients with STRA did show enhanced
IL-17RA immunoreactivity in submucosa and epithelium as
well as increased mRNA expression of IL-17RA and C on stimu-
lation of PBECs with IL-17A when compared with controls
without asthma. IL-17A and IL-17F both signal through IL-
17RA,25 and have fundamental roles as neutrophil chemoattrac-
tants.26,33 However, we found no association between neutrophils
or IL-17A levels and infection in our patients, albeit molecular
microbiological techniques were not used.
Deficiency in IL-17RA results in impaired neutrophil re-
sponses to allergens in mouse models.45,46 Elevation of IL-
17RA and C suggests a role in neutrophil migration, either via a
direct response to IL-17A or via effector molecules such as IL-
8. Although no significant difference was found between the pa-
tients with STRA with or without intraepithelial neutrophils
with regard to IL-17A and IL-17RA expression in submucosa
or epithelium, there was an indication of higher epithelial IL-
17RA expression in the Neutrophilhigh patients. We found no
increased production of IL-6 in our study, which indicates a spe-
cific IL-17A–driven epithelial response, characterized by the
neutrophil chemoattractants IL-8 and GRO, which were signifi-
cantly increased with IL-17A stimulation of PBECs from patients
with STRA compared with controls. These findings question the
rationale for treating children with STRAwith anti–IL-17A anti-
body. An mAb against IL-17RA, Brodalumab, has shown no
benefit in adult patients with moderate-to-severe asthma47 and
our data suggest that its use in children with STRA is unlikely
to be beneficial.
All the patients with STRA in our study were symptomatic and
had poor control despite a high dose of inhaled steroids.
Corticosteroids have been shown to increase airway neutrophils
in asthma48,49 and molecules that are associated with suppression
of neutrophil apoptosis are upregulated by glucocorticosteroids.
This may be an unwanted effect of asthma therapy. In contrast,
our data indicate that patients with lower epithelial neutrophils
were prescribed higher doses of maintenance inhaled steroids,
suggesting an altered relationship between intraepithelial neutro-
phils and glucocorticosteroids. This suggests that the neutrophil
low group may be less sensitive to steroids because group mem-
bers were on a higher median dose as a group.We have shown an association between increased IL-17RA
expression and STRA. IL-17A–induced epithelial secretion of IL-
8 was also unaffected by the presence of budesonide. Previous
studies have also shown a lack of effect of dexamethasone on IL-
17A production from PBMCs in both mice and humans.27,43
These data suggest a lack of association between IL-17A and ste-
roids in patients with severe asthma. Interestingly, it has been
shown that the release of GRO and IL-8 induced by IL-17 in
the bronchial epithelial cell line 16-human bronchial epithelium
is sensitive to hydrocortisone treatment.50 We have found similar
results with this immortalized cell line (see Fig E4 in this article’s
Online Repository at www.jacionline.org), confirming critical
functional differences between PBECs and 16-human bronchial
epitheliums and emphasizing the importance of using primary
cells from patients with asthma.
The strengths of this study include the large number of
carefully characterized children with STRA, a phenotype of
asthma that has been little studied, and the comparison of
clinical parameters with morphological studies and functional
in vitro assays using primary airway epithelial cells from the
same patients. However, we acknowledge some limitations.
We did not include a control group of mild to moderate asthma,
nor did we include true healthy controls. Although an invasive
procedure involving a general anesthetic cannot be ethically
justified for research studies in children, the controls included
did not have lower respiratory tract symptoms, and when we
have used similar patients previously we have found meaningful
group differences.5,51,52 In addition, the controls were younger
because isolated upper airway problems are less common in
school-aged children.
In conclusion, our study shows that children with STRA
compared with younger controls without asthma have an
exaggerated epithelial response to IL-17A, with increased
expression of IL-17RA in the airway submucosa and epithelium.
PBECs from children with STRA responded to IL-17A stimula-
tion with elevated production of the neutrophil-attracting medi-
ators IL-8 and GRO compared with controls. Furthermore,
increased numbers of neutrophils were found only in the
epithelial compartment in a subgroup of children with STRA
and this finding was associated with better lung function, better
symptom control, and lower dose maintenance inhaled steroids.
The critical role of the bronchial epithelium and its interactions
with airway leukocytes in determining downstream functional
effects has been highlighted. Our study shows that there are 2
subgroups within the pediatric STRA phenotype: intraepithelial
Neutrophilhigh and Neutrophillow, further demonstrating that
STRA is heterogeneous and requires careful subphenotyping to
identify optimal personalized molecular therapies.
We thank all the patients and their families for agreeing to take part in our
study. We thank Lorraine Lawrence for histology support. We thank Prof
Stephen Durham and group members for support with the Milliplex assay. We
are also grateful to the Paediatric Respiratory Consultants at the Royal
Brompton Hospital for their help in sample collection during the
bronchoscopies.Clinical implications: Our findings suggest that airway neutro-
philia in pediatric patients with STRA may be a beneficial host
response, and thus should be enhanced not reduced
therapeutically.
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Subjects
Fifty-one school-aged children with STRA who were undergoing a
clinically indicated bronchoscopy were recruited from the Royal Brompton
Hospital between 2009 and 2015. Patients remained poorly controlled despite
being prescribed high doses of inhaled steroids (800 mg/d budesonide or
equivalent) and receiving additional long-acting b-agonists, and current or a
previous failed trial of montelukast (Table I). Twelve percent of the patients
with severe asthma were also taking regular oral steroids. Only children
with true STRAwere included in the study.E1-E3 Those with difficult asthma,
in whom underlying modifiable factors such as persistent allergen exposure,
poor adherence, and/or inhaler technique that might contribute to poor asthma
control, were excluded.E4 The remaining childrenwith STRAunderwent inva-
sive analysis with bronchoscopy, bronchial brushings, BAL, and endobron-
chial biopsies to characterize airway pathology and develop customized
treatment plans. Atopy was defined as 1 or more positive specific IgE RAST
(>_0.34 kU/L) or 1 or more positive skin prick test results to aeroallergens.
Asthma control was assessed by using the ACTE5,E6; poor controlwas defined
as a score of less than 20 of 25. Spirometry and bronchodilator reversibility
defined as a greater than 12% change from baseline FEV1 were measured
according to American Thoracic Society/European Thoracic Society
guidelines.E7,E8 Exhaled nitric oxide measurements at a flow rate of
50 mL/s were made with a chemiluminescence analyzer (NIOX; Aerocrine
AB, Solna, Sweden) in accordancewith American Thoracic Society/European
Thoracic Society guidelines.E9 Clinical details of children with STRA are pre-
sented in Table I. Fifteen control subjects without asthma were either having a
bronchoscopy to investigate upper airway symptoms and agreed to extra
research samples being taken or were undergoing general anesthesia for
cardiac symptoms and agreed to have a research bronchoscopy at the same
time (see Table I and Table E2 for details). The study was approved by the
Brompton and Harefield National Heart and Lung Institute’s Ethics
Committee, and informed parental consent and child assent were obtained.
Findings relating to epithelial inflammation in this groupwere confirmed in
biopsies already obtained from a previously published cohort of children with
STRA (n5 21) and controls without asthma (n5 5) (Table E1). The inclusion
criteria in this cohort were the same as for the patients described above (see
also Bossley et alE1). Children aged 5 to 16 years with STRAwere included.
Definitions of uncontrolled disease and entry criteria were as follows:
1. Persistent (most days for >_3 months) chronic symptoms (use of short-
acting b2-agonists >_3 times per week) of airway obstruction despite
high doses of inhaled corticosteroids (>_800 mg/d budesonide equiva-
lent) and/or regular oral corticosteroids, long-acting b2-agonists, and
current (or previous failed trial of) montelukast.
2. Recurrent severe exacerbations requiring 1 or more admission to the
intensive care unit or 2 or more hospital admissions requiring intrave-
nous medications or 2 or more courses of oral corticosteroids in the
past year despite therapy for persistent symptoms as described above.
3. At least 1 very sudden (<_6 hours) severe attack (requiring hospitaliza-
tion) without warning despite therapy for persistent symptoms, as
described above.
Evaluations were performed to assess medication, dose, device and
technique, atopic status, asthma understanding, adherence, environment,
and any psychosocial issues. After assessment, those classified as true
STRAwere further investigated. The study was approved by the local research
ethics committee, and all procedures were performed after obtaining written
informed parental consent and, where appropriate, child assent.
Epithelial cell culture and stimulation
Epithelial brushings were obtained at bronchoscopy using a fiberoptic
bronchoscope (Olympus, Keymed, United Kingdom). A sterile single-sheathed
nylon cytology brush was used to sample epithelial cells from the bronchial
mucosa of the second- and third-generation bronchi. Cells were transferred to
5-mLbronchial epithelial growthmedium (BEGM,Lonza,Walkerville,Md) and
the samples were centrifuged at 1500g for 5minutes to pellet the cells. Primary
cultures were established by reconstituting the pellet in BEGM and cells wereseeded into collagen-coated T25 tissue culture flasks containing 5 mL BEGM.
Cultures were routinely tested for mycoplasma infection.
Primary pediatric bronchial epithelial cells were grown to 80% to 90%
confluence in 12-well plates. On the day of stimulation, the growth medium
was replaced with bronchial epithelial basal medium (Lonza) 4 hours before
the start of the experiment. The primary epithelial cells were used at passage 3
for all experiments. PBECs were stimulated with recombinant human IL-17A
(eBioscience) and IL-22 (eBioscience) at 10 ng/mL alone, or with added
budesonide at a final concentration of 1028 mol/L. All experiments were done
in triplicate. After 24-hour cell culture, supernatants were taken, and cell
lysates were prepared in RIPA buffer containing protease inhibitor tablets
(Roche Diagnostics, Mannheim, Germany). Samples for mRNA extraction
were undertaken in separate 12-well plates and cells were harvested in Trizol
(Sigma, St Louis, Mo) after 8-hour stimulation.
Sixteen human bronchial epitheliums (HBEs), a differentiated SV-40–
transformed bronchial epithelial cell line, was used in the same way as the
primary human bronchial epithelial cells and stimulated as described abovewith
IL-17, IL-22, IL-17, and IL-22 in combination with or without budesonide.
Quantification of cytokines
Cell culture supernatant was collected and cytokines were analyzed using
ELISA andMilliplex. Milliplex human cytokine panel I and II (HCYP2MAG-
62K and MPXHCYTO-60K, Millipore Corporation, Billerica, Mass) were
used to detect levels of IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-13, IL-17, IP-10,
MCP-1, MDC, RANTES, TNF-a, VEGF, eotaxin, eotaxin-2, eotaxin-3,
fibroblast growth factor 2 (FGF2), growth-regulated oncogene (GRO),
thymus and activation regulated chemokine (TARC/CCL17), stem cell
factor (SCF), thymic stromal lymphopoietin (TSLP), and IL-33 according
to manufacturer’s instructions. Levels of IL-6 and IL-8 were confirmed with
standardized sandwich ELISAs, according to the manufacturer’s protocol
(88-8086 and 88-7066, eBiosciences).
Cytomix
BAL fluid cytokine quantification was performed using Flowcytomix
Human TH1/TH2/TH9/TH17/TH22 13 plex multiplex (eBioscience) to detect
levels of IFN-g, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p70),
IL-13, IL-17A, IL-22, and TNF-a according to manufacturer’s instructions.
Samples were assayed using the BD Fortessa flow cytometer. Data analysis
was performed using Flowcytomix software (eBioscience) and GraphPad
Prism (V.6 for Mac OS X, GraphPad Software Inc, San Diego, Calif).
Fluorescence-activated cell sorting
Lymphocytes used for compensations and fluorescence minus ones were
extracted from peripheral blood using a density gradient medium (Lympho-
prepTM). Cell concentration was optimized to 2 to 43 105 cells per 100 mL.
Cells from the airway lumen were obtained after centrifuge of BAL fluid to
obtain a cell pellet. Cells were resuspended in RPMI complete and plated at
2 to 43 105 cells per 100 mL. Cells were stimulated for 4 hours with phorbol
12-myristate 13-acetate (PMA), ionomycin, and Brefeldin A. Cells were
stained for extracellular markers CD3 (1:50), CD4 (1:50), CD8, CD161,
and gdTCR and intracellular staining for IL-17A (eBiosciences, mouse anti-
human 5 mL per well).
Samples were assayed using the BDFortessa flow cytometer (BD, Oxford,
United Kingdom). Data were analyzed using FlowJo (V.9.2, TreeStar Inc,
Ashland,Ore) andGraphPadPrism (V.6 forMacOSX,GraphPadSoftware Inc).
RNA extraction and real-time PCR
Total RNAwas extracted from epithelial cells by using the Qiagen RNeasy
Mini Kit (Qiagen, Hilden, Germany). cDNAwas synthesized from 500 ng of
total RNA and analyzed by using High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems). Reactions were run with TaqMan primers against
IL-17RA, IL-17RC, Fibronectin, Collagen I (Applied Biosystems), and
TaqMan Fast Advanced Master Mix (Applied Biosystems) according to
manufacturer’s directions on a Viaa-7 (Life Technologies, Basingstoke,
United Kingdom) instrument and gene expression was analyzed using the
change-in-threshold DDCt- method.
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Endobronchial biopsies were processed to paraffin. Five-micrometer
sections were stained with hematoxylin and eosin and used to assess
morphology, and consecutive sections were used for Masson’s trichrome
staining (Sigma Aldrich) and immunohistochemical staining for IL-17A, IL-
17RA, and neutrophil elastase. Human polyclonal goat anti–IL-17 antibody
(R&D, Rocky Hill, NJ; dilution 1:50) and human monoclonal mouse anti–IL-
17RA antibody (R&D; dilution 1:50) were detected by using Dako EnVision
(K5007) or anti-goat horseradish peroxidase (Dako, Glostrup, Denmark).
Staining was visualized with 39,39-diaminobenzidine (DAB kit, Vector
Laboratories, Peterborough, United Kingdom) and counterstained with
hematoxylin. Human monoclonal mouse antielastase (Dako, dilution 1:100)
was used for detection of neutrophils. Primary was detected with Vector
Laboratories ABC kit (AK5000) according to manufacturer’s instructions and
was visualized with Fast Red and counterstained with hematoxylin. IL-17A–
positive cells were quantified in the submucosa and expressed as cells per
square millimeter of tissue using ImageScope (Aperio, Vista, Calif). IL-17RA
was quantified using ImageScope positive pixel count algorithm in the
submucosa and epithelium and expressed as positive pixels divided by total
number of pixels (positivity). Neutrophil density was quantified in the
epithelium and the subepithelial compartment using ImageScope. Neutrophils
in the submucosa were expressed as cells per square millimeter tissue and
intraepithelial neutrophils as the proportion of intraepithelial neutrophils of all
neutrophils present in the biopsy as well as number of cells per micrometer
reticular basal membrane length. Because only a proportion of patients with
STRA had intraepithelial neutrophils, we included biopsies from another
cohort with similar patients (patients’ details have been previously publish-
edE1) to be able to do a statistically assured comparison and correlation to
FEV1 % predicted.
Double staining with immunofluorescence was used to simultaneously
visualize IL-17A together with the followingmolecules: CD68 (1:200, Dako),
elastase (1:200, Dako), tryptase (Dako), and CD3 (1:50, Dako). The markers
were selected to represent multiple leukocyte populations that might express
IL-17A. After antigen retrieval (citrate buffer, pH 6), sections were stained for
IL-17A using specific and validated primary antibody (IL-17A, R&D
Systems) and visualized by an Alexa-Flour 555–conjugated secondary
antibody (Molecular Probes, Eugene, Ore). Next, antibodies against CD68,
elastase, tryptase, or CD3 were added and visualized using an AlexaF-488–
conjugated secondary antibody. Sections were mounted with Prolong gold
mounting medium with 49-6-diamidino-2-phenylindole, dihydrochloride
(Molecular Probes) for visualization of cell nuclei.
Statistical analysis
Nonparametric Mann-Whitney U tests and Kruskal Wallis test with Bonfer-
ronipost hoc testwere used todetect differencesbetween2groups ormore than2
groups, respectively, by using GraphPad Prism 6 software (GraphPad Software,
La Jolla, Calif). Correlationswere assessed by using the Spearman rank correla-
tion test. Results were considered significant at a P value of less than .05.
RESULTS
Stimulation of bronchial epithelial cells with IL-
17A–induced secretion of GRO in children with
STRA
Because IL-17A is associated with increased numbers of
neutrophils in adults with asthma, levels of GRO were measured
in BAL fluid as well as in PBEC culture supernatants following
IL-17A and IL-22 stimulation, with or without budesonide.
Epithelial GRO secretion from bronchial epithelial cells was
significantly increased in patients with STRA compared with
controls without asthma with IL-17A stimulation in combination
with budesonide (Fig E1, A). No effect was seen with IL-22 stim-
ulation alone.
Detectable levels of IL-6, IL-8, IL-13, IP-10, MCP-1, MDC,
FGF-2, and IFN-g were also found in cell culture supernatantsusing Milliplex but no difference was found between children
with STRA and controls without asthma expect for IL-8, which
confirmed the ELISA data (Fig E2, B). The other mediators in the
Milliplex kit were below detection level.
Correlations between specific serum IgE levels and
clinical parameters, neutrophil numbers, and IL-
17A/RA expression
We did not find any correlation of submucosal or intraepithelial
neutrophils, IL-17A, and IL-17RA expression to specific IgE
(sIgE) levels to any specific allergen nor to the sum of inhaled
allergen or to the total sum of sIgE to all allergens. However,
positive correlations were found between sum of sIgE to inhaled
allergens and reticular basement membrane (RBM) thickness
(rs5 0.43; P5 .05) and sum of sIgE to inhaled allergens and sub-
mucosal eosinophils (rs 5 0.63; P 5 .03).
16-HBEs cell line appears to be sensitive to
treatment with budesonide
In contrast to the primary HBECs, the 16HBE cell line did
not respond with increased IL-6 and IL-8 production on
stimulation with IL-17A, IL-22, or in combination. However,
they did display sensitivity to budesonide and showed decreased
production of IL-6 and IL-8 on treatment with budesonide (Fig
E3, A and B).
IL-17A stimulation induced epithelial expression of
remodeling mediators
Increased RBM thickness and airway smooth muscle mass are
distinct features of children with STRA.E1 Because IL-17A and
IL-22 have been associated with airway remodeling,E10-E12 we
measured epithelial secretion of remodeling mediators in
response to stimulation with these cytokines. VEGF was signifi-
cantly increased in children with STRA compared with controls
without asthma when IL-17A and IL-22 were used in combina-
tion (Fig E5, A; P 5 .04). Fibronectin mRNA was increased in
children with STRA compared with controls without asthma
when cells were stimulated with IL-17A alone (P 5 .02; Fig
E5, B), while collagen I was increased in children with STRA
compared with controls without asthma when cells were stimu-
lated with IL-22 (P5 .02), IL-17 (P5 .005), or IL-17 with bude-
sonide (P5 .05) (Fig E5, C). We confirmed our previous findings
(1) that children with STRA have increased RBM thickness
(P5.03; Fig E5,E). However, no significant difference in submu-
cosal collagen deposition was found in bronchial biopsies from
controls without asthma and patients with STRA (P 5 .09; Fig
E3, F and G).
E5. Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, et al. Asthma
Control Test: reliability, validity, and responsiveness in patients not previously
followed by asthma specialists. J Allergy Clin Immunol 2006;117:549-56.
E6. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Devel-
opment of the asthma control test: a survey for assessing asthma control.
J Allergy Clin Immunol 2004;113:59-65.
E7. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.
Standardisation of spirometry. Eur Respir J 2005;26:319-38.
E8. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Inter-
pretative strategies for lung function tests. Eur Respir J 2005;26:948-68.
E9. American Thoracic Society. European Respiratory Society. ATS/ERS recom-
mendations for standardized procedures for the online and offline measurement
of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit
Care Med 2005;2005(171):912-30.
E10. Chang Y, Al-Alwan L, Risse PA, Halayko AJ, Martin JG, Baglole CJ, et al.
Th17-associated cytokines promote human airway smooth muscle cell prolifer-
ation. FASEB J 2012;26:5152-60.
E11. Johnson JR, Nishioka M, Chakir J, Risse PA, Almaghlouth I, Bazarbashi
AN, et al. IL-22 contributes to TGF-beta1-mediated epithelial-mesen-
chymal transition in asthmatic bronchial epithelial cells. Respir Res
2013;14:118.
E12. Pociask DA, Scheller EV, Mandalapu S, McHugh KJ, Enelow RI, Fattman CL,
et al. IL-22 is essential for lung epithelial repair following influenza infection.
Am J Pathol 2013;182:1286-96.
J ALLERGY CLIN IMMUNOL
nnn 2016
11.e3 ANDERSSON ET AL
FIG E1. Measurement of GRO in culture supernatants from PBECs after
stimulation with IL-17A, IL-22, and budesonide (Bud) (Fig E1, A) (controls
without asthma n 5 4, STRA n 5 4). Statistical significance between con-
trols without asthma and STRAwas tested usingMann-Whitney test, where
a *P value of less than .05 was considered significant.
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FIG E2. Tissue density of IL-17A in submucosa (A), IL-17RA in submucosa (B), and IL-17RA in epithelium (C)
in bronchial biopsies from children with STRA divided into Neutrophilhigh vs Neutrophillow groups. Statis-
tical significance was tested using Mann-Whitney test, where a P value of less than .05 was considered sig-
nificant. Neu, Neutrophil.
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FIG E3. Measurement of IL-6 (A), IL-8 (B), IL-13 (C), IP-10 (D),MCP-1 (E),MDC (F), FGF-2 (G), and IFN-g (H) in
culture supernatants from PBECs after stimulation with IL-17A, IL-22, and budesonide (Bud) (controls
without asthma n 5 4, STRA n 5 4) using Milliplex assay. Statistical significance between controls without
asthma and STRA was tested using Mann-Whitney test, where a *P value of less than .05 was considered
significant.
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FIG E4. Measurement of IL-6 (A) and IL-8 (B) in culture supernatants from 16HBEs after stimulation with IL-
17A, IL-22, and budesonide (Bud) using ELISA.
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FIG E5. The effect of IL-17A on airway remodeling parameters. Measurement of VEGF in culture
supernatants from PBECs after stimulation with IL-17A, IL-22, and budesonide (A) (controls without asthma
n5 4, STRA n5 4). mRNA expression in PBECs after stimulation with IL-17A, IL-22, and budesonide of fibro-
nectin (B) and collagen I (C) (controls without asthma n5 3, STRA n5 3). RBM thickness in controls without
asthma compared with STRA (D) (controls without asthma n 5 7, STRA n 5 21) and RBM thickness within
the STRA group when divided into Neutrophilhigh subgroup vs Neutrophillow subgroup (E). Representative
micrographs of bronchial biopsies stained with Masson’s trichrome staining for collagen (blue) (F control
and G STRA). Subepithelial collagen deposition (H) (nonasthmatic controls n 5 7, STRA n 5 9) in bronchial
biopsies from controls without asthma and children with STRA expressed as positive pixels per area. Sta-
tistical significance between controls without asthma and STRA was tested using Mann-Whitney test,
where a *P value of less than .05 was considered significant.
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FIG E6. Immunohistochemical double staining of bronchial biopsies of IL-17A (red, AlexaF 555) and
elastase (A) or CD3 (B) (green, AlexaF 488). Corresponding isotype controls are shown in C and D.Nuclei are
stained blue with DAPI. DAPI, 4’-6-Diamidino-2-phenylindole, dihydrochloride; IHC, immunohistochem-
istry. Scale bar: 100 mm.
J ALLERGY CLIN IMMUNOL
nnn 2016
11.e9 ANDERSSON ET AL
TABLE E1. Demographic characteristics of patients with STRA and controls undergoing bronchoscopy in validation cohort
collected between 2007 and 2009
Characteristic STRA (n 5 21) Healthy control (n 5 5) P value
Atopy 21 of 21 (100%) 0 of 5 (0%)
Male:female 14:7 3:2
Age (y) 11.2 (8 to 16) 11.2 (9 to 16) .80
Weight (kg) 42.4 (24.1 to 74.0) 44.7 (37.8 to 60.2) .96
Height (cm) 141 (114 to 159) 160 (144 to 168) .054
Total IgE (IU/mL) 415 (16 to 18645) —
BAL neutrophils (%)* 3 (0 to 19) 1.3 (0 to 14) .22
BAL eosinophils (%) 3 (0 to 51) 0 (0 to 10) .33
ACT score 11 (6 to 22) —
Baseline % predicted FEV1§ 69 (29 to 98) 98 (78 to 106) .0072
Number FEV1 ‘‘normal’’ (>80% predicted) 6 of 21 (28.6%) 4 of 5 (80%)
Baseline % predicted FVC 99.5 (63 to 133) 93 (89 to 116) .56
Baseline bronchodilator reversibility (%) 13.3 (22 to 135) —
Medications
Daily dose inhaledk corticosteroid (mg/d) budesonide equivalent 1600 (800 to 3200) 0
Systemic corticosteroids 12 of 21 (57%) 0
Daily dose (mg/d) 6.88 (5 to 40) 0
Data presented as median (range).
*BAL neutrophils (<3% is normal).
BAL eosinophils (<3% is normal).
Asthma control test (>19 is normal).
§FEV1: presented as percentage predicted.
kICS: inhaled corticosteroids/d. Differences between groups were assessed by Mann-Whitney test where P < .05 is significant.
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TABLE E2. Clinical diagnosis and reason for bronchoscopy of
controls without asthma
Clinical diagnosis
Controls without asthma
(n 5 15)
Elective cardiac catheter 2
Unexplained hypoxia 1
Reflux 2
Tracheal stenosis 2
Chronic dry cough 5
Hemoptysis 2
Laryngotracheomalacia 1
Data presented as number of patients.
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